Christina Pachel1, Denise Mathes1, Anahi-Paula Arias-Loza1, Wolfram Heitzmann1, Peter Nordbeck1, Carsten Deppermann1, Viola Lorenz1, Ulrich Hofmann1, Bernhard Nieswandt1, Stefan Frantz2. 1. From the Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (C.P., D.M., A.-P.A.-L., W.H., P.N., U.H., S.F.); Hospital Pharmacy, Jena University Hospital, Jena, Germany (D.M.); Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany (U.H., S.F.); Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine, Würzburg, Germany (C.D., V.L., B.N.); Division of Newborn Medicine, Boston Children's Hospital, Boston (V.L.); and Universitätsklinik und Poliklinik für Innere Medizin III, Universitätsklinikum Halle (Saale), Halle (Saale), Germany (U.H., S.F.). 2. From the Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany (C.P., D.M., A.-P.A.-L., W.H., P.N., U.H., S.F.); Hospital Pharmacy, Jena University Hospital, Jena, Germany (D.M.); Comprehensive Heart Failure Center, University Hospital Würzburg, Würzburg, Germany (U.H., S.F.); Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine, Würzburg, Germany (C.D., V.L., B.N.); Division of Newborn Medicine, Boston Children's Hospital, Boston (V.L.); and Universitätsklinik und Poliklinik für Innere Medizin III, Universitätsklinikum Halle (Saale), Halle (Saale), Germany (U.H., S.F.). stefan.frantz@uk-halle.de.
Abstract
OBJECTIVE: The objective of this study was to investigate the effects of platelet inhibition on myocardial ischemia-reperfusion (IR) injury. APPROACH AND RESULTS: Timely restoration of coronary blood flow after myocardial infarction is indispensable but leads to additional damage to the heart (myocardial IR injury). Microvascular dysfunction contributes to myocardial IR injury. We hypothesized that platelet activation during IR determines microvascular perfusion and thereby the infarct size in the reperfused myocardium. The 3 phases of thrombus formation were analyzed by targeting individual key platelet-surface molecules with monoclonal antibody derivatives: (1) adhesion (anti-glycoprotein [GP]-Ib), (2) activation (anti-GPVI), and (3) aggregation (anti-GPIIbIIIa) in a murine in vivo model of left coronary artery ligation (30 minutes of ischemia followed by 24 hours of reperfusion). Infarct sizes were determined by Evans Blue/2,3,5-triphenyltetrazolium chloride staining, infiltrating neutrophils by immunohistology. Anti-GPVI treatment significantly reduced infarct size versus control, whereas anti-GPIb or anti-GPIIbIIIa antibody fragments showed no significant differences. Mechanistically, anti-GPVI antibody-mediated reduction of infarct size was not because of impaired Ca(2+) signaling or platelet degranulation because mice deficient in store-operated calcium channels (stromal interaction molecule 1, ORAI1), α-granules (Nbeal2(-/-)), and dense granule release (Unc13d(-/-)) had similar infarct sizes as control animals. Protective effects of anti-GPVI treatment were accompanied by improved microperfusion. Leukocyte infiltration was reduced in both anti-GPVI and anti-GPIb-treated IR mice. CONCLUSIONS: Inhibition of platelet activation by an anti-GPVI antibody, but not inhibition of platelet adhesion or aggregation by an anti-GPIb or anti-GPIIbIIIa antibody significantly reduces infarct size. The reduction of the infarct size is primarily based on an improved microperfusion after anti-GPVI antibody treatment.
OBJECTIVE: The objective of this study was to investigate the effects of platelet inhibition on myocardial ischemia-reperfusion (IR) injury. APPROACH AND RESULTS: Timely restoration of coronary blood flow after myocardial infarction is indispensable but leads to additional damage to the heart (myocardial IR injury). Microvascular dysfunction contributes to myocardial IR injury. We hypothesized that platelet activation during IR determines microvascular perfusion and thereby the infarct size in the reperfused myocardium. The 3 phases of thrombus formation were analyzed by targeting individual key platelet-surface molecules with monoclonal antibody derivatives: (1) adhesion (anti-glycoprotein [GP]-Ib), (2) activation (anti-GPVI), and (3) aggregation (anti-GPIIbIIIa) in a murine in vivo model of left coronary artery ligation (30 minutes of ischemia followed by 24 hours of reperfusion). Infarct sizes were determined by Evans Blue/2,3,5-triphenyltetrazolium chloride staining, infiltrating neutrophils by immunohistology. Anti-GPVI treatment significantly reduced infarct size versus control, whereas anti-GPIb or anti-GPIIbIIIa antibody fragments showed no significant differences. Mechanistically, anti-GPVI antibody-mediated reduction of infarct size was not because of impaired Ca(2+) signaling or platelet degranulation because mice deficient in store-operated calcium channels (stromal interaction molecule 1, ORAI1), α-granules (Nbeal2(-/-)), and dense granule release (Unc13d(-/-)) had similar infarct sizes as control animals. Protective effects of anti-GPVI treatment were accompanied by improved microperfusion. Leukocyte infiltration was reduced in both anti-GPVI and anti-GPIb-treated IR mice. CONCLUSIONS: Inhibition of platelet activation by an anti-GPVI antibody, but not inhibition of platelet adhesion or aggregation by an anti-GPIb or anti-GPIIbIIIa antibody significantly reduces infarct size. The reduction of the infarct size is primarily based on an improved microperfusion after anti-GPVI antibody treatment.
Authors: Derek J Hausenloy; William Chilian; Filippo Crea; Sean M Davidson; Peter Ferdinandy; David Garcia-Dorado; Niels van Royen; Rainer Schulz; Gerd Heusch Journal: Cardiovasc Res Date: 2019-06-01 Impact factor: 10.787
Authors: Holly Foster; Clare Wilson; Julia S Gauer; Rui-Gang Xu; Mark J Howard; Iain W Manfield; Robert Ariëns; Khalid Naseem; Lewis R Vidler; Helen Philippou; Richard Foster Journal: ACS Med Chem Lett Date: 2022-01-20 Impact factor: 4.345
Authors: Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty Journal: Arterioscler Thromb Vasc Biol Date: 2018-10 Impact factor: 8.311
Authors: Kirsten A Kortekaas; Dorottya K de Vries; Mark Roest; Marlies Ej Reinders; Eric P van der Veer; Robert Jm Klautz; Philip G de Groot; Alexander F Schaapherder; Jan H Lindeman Journal: Am J Transl Res Date: 2018-03-15 Impact factor: 4.060
Authors: Xiaohong Ruby Xu; Naadiya Carrim; Miguel Antonio Dias Neves; Thomas McKeown; Tyler W Stratton; Rodrigo Matos Pinto Coelho; Xi Lei; Pingguo Chen; Jianhua Xu; Xiangrong Dai; Benjamin Xiaoyi Li; Heyu Ni Journal: Thromb J Date: 2016-10-04